Yahoo · Oct 8, 2026
Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications.
NASDAQ · LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
$1,188.72
Down-$18.79 (-1.58%)
Updated Oct 9, 2026, 1:48 AM
SID Score
6.1/10
Composite research score
Smart Money
44/100
Neutral
- Market cap
- 906.5B
- P/E ratio
- 49.16
- Dividend yield
- 0.65%
- 52-week range
- $850.51 – $1,292.65
- Volume
- 2.31M
- Avg. volume
- 3.8M
Price performance · LLY
LLY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
LLY closed at $1,188.72 after 20 trading sessions, up 5.85% for the selected period.
- Last close
- $1,188.72
- Period change
- +5.85%
- Period low
- $1,115.70
- Period high
- $1,188.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1,173.62 | $1,206.63 | $1,166.00 | $1,188.72 | 2.31M |
| Oct 6, 2026 | $1,147.15 | $1,177.065 | $1,139.98 | $1,157.49 | 2.13M |
| Oct 5, 2026 | $1,150.76 | $1,165.73 | $1,139.495 | $1,143.12 | 1.98M |
| Oct 2, 2026 | $1,153.82 | $1,164.9155 | $1,136.66 | $1,142.85 | 2.05M |
| Oct 1, 2026 | $1,155.00 | $1,158.72 | $1,139.85 | $1,149.85 | 2.17M |
| Sep 30, 2026 | $1,186.49 | $1,215.00 | $1,155.27 | $1,157.08 | 3.41M |
| Sep 29, 2026 | $1,186.05 | $1,192.94 | $1,168.471 | $1,184.63 | 1.66M |
| Sep 28, 2026 | $1,180.30 | $1,194.09 | $1,172.56 | $1,184.78 | 1.97M |
| Sep 25, 2026 | $1,185.32 | $1,190.00 | $1,160.84 | $1,183.46 | 1.92M |
| Sep 24, 2026 | $1,156.67 | $1,197.79 | $1,151.00 | $1,181.89 | 2.42M |
| Sep 23, 2026 | $1,174.71 | $1,188.88 | $1,145.98 | $1,150.99 | 2.16M |
| Sep 22, 2026 | $1,146.15 | $1,180.53 | $1,139.26 | $1,170.14 | 2.45M |
| Sep 21, 2026 | $1,144.495 | $1,170.8999 | $1,134.41 | $1,164.89 | 2.48M |
| Sep 18, 2026 | $1,150.00 | $1,157.60 | $1,140.27 | $1,152.93 | 4.55M |
| Sep 17, 2026 | $1,150.27 | $1,159.75 | $1,138.26 | $1,152.44 | 1.9M |
| Sep 16, 2026 | $1,137.31 | $1,151.23 | $1,132.63 | $1,137.82 | 1.48M |
| Sep 15, 2026 | $1,156.63 | $1,161.00 | $1,131.59 | $1,136.11 | 1.89M |
| Sep 14, 2026 | $1,142.20 | $1,153.95 | $1,130.5001 | $1,138.28 | 2.13M |
| Sep 11, 2026 | $1,129.405 | $1,131.44 | $1,113.2919 | $1,115.70 | 1.84M |
| Sep 10, 2026 | $1,126.08 | $1,133.79 | $1,120.52 | $1,123.00 | 2M |
Latest LLY news
The latest Smart Investors Daily articles mentioning LLY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LLY research
Overview
Company profile and research snapshot.
Company profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $1,055.92
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 7, 2026 | Morgan Stanley | Overweight | — |
| Sep 28, 2026 | JP Morgan | Overweight | — |
| Sep 22, 2026 | TD Cowen | Buy | — |
| Sep 18, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Oct 8, 2026
Stay informed with the top movers within the S&P500 index on Thursday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
ChartMill · Oct 8, 2026
Which S&P500 stocks are gapping on Thursday?
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.
Yahoo · Oct 8, 2026
Eli Lilly (LLY) Has a Powerful Growth Flywheel Beyond Its GLP-1 Success
Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund navigated a mixed third-quarter investment environment in which rising oil prices, higher interest rates, and persistent inflation created headwinds for equities and bonds, although strong corporate earnings and continued AI investment helped support […]
AI research layers
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company Stock Performance
Eli Lilly and Company shares traded at $1,188.72, reflecting a single-session decline of 1.66% per SID market data. Over the trailing one-month period, LLY posted a modest gain of 0.71%, while the three-month return registered a decline of 4.8%. On a twelve-month basis, the stock gained 7.53%, underperforming the broader healthcare sector's typical growth trajectory. Technical indicators show LLY trading above both its 50-day moving average of $1,174.93 and its 200-day moving average of $1,068.82, according to Massive/Polygon data, suggesting the longer-term uptrend remains intact despite near-term weakness. The 14-day RSI stands at 56.9, positioning the stock in neutral territory between overbought and oversold conditions. LLY's beta of 0.369 indicates significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 3.8 million shares, supporting adequate liquidity for institutional participation.
Eli Lilly and Company Valuation Analysis
Eli Lilly carries a market capitalization of approximately $906.5 billion, positioning it among the largest companies in the global healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 49.16, a substantial premium relative to the broader S&P 500 and most pharmaceutical peers, reflecting elevated growth expectations tied to its GLP-1 receptor agonist portfolio. The PEG ratio stands at 1.47, according to SEC filings, suggesting the premium valuation is partially justified by projected earnings growth but remains above the commonly referenced fair-value threshold of 1.0. LLY's price-to-book ratio of 38.04 further underscores the market's willingness to pay a significant premium for the company's intangible assets and pipeline potential. The current dividend yield of 0.59% remains modest, indicating the company prioritizes reinvestment in research and development over shareholder capital returns through dividends.
Smart Money Activity for LLY
Eli Lilly's composite smart money score stands at 44 out of 100, registering a neutral signal according to SID market data. The institutional component scores a perfect 25 out of 25, indicating strong and sustained institutional ownership and accumulation, which reflects high conviction among large asset managers. In contrast, the insider sentiment score of 7.2 out of 25 is relatively subdued. Per SEC Form 4 filings, there have been 16 insider transactions over the past 90 days, comprising 9 purchases and 7 sales. The near-balanced ratio of insider buys to sells suggests no decisive directional conviction from company executives. The dark pool activity score of 9.1 out of 25 indicates moderate off-exchange trading interest. Congressional trading activity scores 3.2 out of 25, according to 13F institutional filings, reflecting minimal disclosed legislative trading in LLY shares. The divergence between exceptionally strong institutional positioning and weaker insider and dark pool signals produces the overall neutral composite reading.
Eli Lilly and Company Earnings Outlook
Eli Lilly has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the quarter reported on August 5, 2026, actual earnings per share of $8.38 exceeded the consensus estimate of $6.01 by $2.37, representing a 39.4% upside surprise. The quarter reported on April 30, 2026, showed actual EPS of $8.55 versus the $6.85 estimate, delivering a $1.70 positive surprise. These substantial beats highlight the accelerating revenue contribution from Eli Lilly's key growth franchises. Looking ahead, analyst estimates project continued EPS expansion, with the August 6, 2026 quarter estimated at $8.84 and the October 29, 2026 quarter estimated at $9.93, per consensus analyst estimates. The sequential increase in forward estimates suggests Wall Street anticipates sustained top-line momentum, with full-year earnings growth trajectory remaining robust relative to historical pharmaceutical industry norms.
Wall Street Analyst Ratings for LLY
Wall Street consensus on Eli Lilly remains predominantly bullish, with four of the five most recent analyst actions carrying positive ratings, per Wall Street analyst reports. On October 7, 2026, Morgan Stanley reiterated its Overweight rating, while JP Morgan maintained its Overweight call on September 28, 2026. TD Cowen reiterated a Buy rating on September 22, and Guggenheim affirmed its Buy on September 18. The sole dissenting view comes from HSBC, which maintained a Reduce rating on September 10, 2026, according to SID consensus data. Notably, all five recent actions were reiterations of existing ratings rather than upgrades or downgrades, indicating analyst conviction has stabilized at current levels. The 80% bullish consensus among recent coverage reflects confidence in Eli Lilly's commercial execution around its GLP-1 portfolio. The absence of any downgrades across these analyst updates suggests the fundamental thesis remains intact despite the stock's elevated valuation multiples.
